$MBRX
Moleculin Biotech, Inc. Stock $mbrx

$mbrx Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000165961717000005 Filed on November 13, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.100M	$1.340M	$530.0K
YoY Change	107.55%	45.65%
% of Gross Profit
Research & Development	$2.290M	$1.061M	$880.0K
YoY Change	160.23%	113.48%
% of Gross Profit
Depreciation & Amortization	$10.00K	$5.000K	$10.00K
YoY Change	0.0%	400.0%
% of Gross Profit
Operating Expenses	$3.390M	$2.404M	$1.420M
YoY Change	138.73%	69.06%
Operating Profit		-$2.404M
YoY Change		69.06%
Interest Expense	$210.0K	$1.000K	-$10.00K
YoY Change	-2200.0%	-90.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	$9.000K
YoY Change
Pretax Income	-$3.190M	-$2.870M	-$1.420M
YoY Change	124.65%	100.7%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$3.190M	-$2.866M	-$1.420M
YoY Change	124.65%	100.14%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$901.1K	-$839.2K	-$1.868M
COMMON SHARES
Basic Shares Outstanding	21.14M shares	20.26M shares	12.05M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.710M	$8.740M	$5.010M
YoY Change	53.89%	41.42%
Cash & Equivalents	$7.714M	$8.736M	$5.007M
Short-Term Investments
Other Short-Term Assets	$590.0K	$730.0K	$220.0K
YoY Change	168.18%	204.17%
Inventory
Prepaid Expenses	$588.0K		$215.0K
Receivables
Other Receivables
Total Short-Term Assets	$8.302M	$9.463M	$5.222M
YoY Change	58.98%	47.2%	18489.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.00K	$22.00K	$23.00K
YoY Change	43.48%	34.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$11.18M	$11.17M	$11.17M
YoY Change	0.09%	0.22%
TOTAL ASSETS
Total Short-Term Assets	$8.302M	$9.463M	$5.222M
Total Long-Term Assets	$11.18M	$11.17M	$11.17M
Total Assets	$19.48M	$20.63M	$16.39M
YoY Change	18.85%	17.41%	58256.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$810.0K	$1.090M	$399.0K
YoY Change	103.01%	11.22%
Accrued Expenses	$902.0K		$650.0K
YoY Change	38.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$300.0K
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$2.215M	$1.832M	$1.345M
YoY Change	64.68%	43.11%	74.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$150.0K	$150.0K	$90.00K
YoY Change	66.67%	200.0%
Total Long-Term Liabilities	$150.0K	$150.0K	$90.00K
YoY Change	66.67%	200.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.215M	$1.832M	$1.345M
Total Long-Term Liabilities	$150.0K	$150.0K	$90.00K
Total Liabilities	$2.365M	$1.982M	$1.433M
YoY Change	65.04%	49.01%	85.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$14.48M	-$11.30M	-$4.675M
YoY Change	209.73%	247.39%	524.7%
Common Stock	$31.60M	$29.95M	$19.64M
YoY Change	60.93%	53.58%	294675.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.12M	$18.65M	$14.96M
YoY Change
Total Liabilities & Shareholders Equity	$19.48M	$20.63M	$16.39M
YoY Change	18.85%	17.41%	58256.77%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q4
OPERATING ACTIVITIES
Net Income	-$3.190M	-$2.866M	-$1.420M
YoY Change	124.65%	100.14%
Depreciation, Depletion And Amortization	$10.00K	$5.000K	$10.00K
YoY Change	0.0%	400.0%
Cash From Operating Activities	-$2.390M	-$1.610M	-$1.160M
YoY Change	106.03%	69.47%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$10.00K	-$10.00K
YoY Change	100.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$20.00K	-$10.00K	-$10.00K
YoY Change	100.0%	-90.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$400.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.380M	1.090M	10.00K
YoY Change	13700.0%
NET CHANGE
Cash From Operating Activities	-2.390M	-1.610M	-1.160M
Cash From Investing Activities	-20.00K	-10.00K	-10.00K
Cash From Financing Activities	1.380M	1.090M	10.00K
Net Change In Cash	-1.030M	-530.0K	-1.160M
YoY Change	-11.21%	-50.0%
FREE CASH FLOW
Cash From Operating Activities	-$2.390M	-$1.610M	-$1.160M
Capital Expenditures	-$20.00K	-$10.00K	-$10.00K
Free Cash Flow	-$2.370M	-$1.600M	-$1.150M
YoY Change	106.09%	70.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	mbrx	Debt Conversion Original Debt Reduction DebtConversionOriginalDebtReduction	300000	USD
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001659617
CY2016Q1	mbrx	Debt Instrument Number Of Unsecured Notes Entered DebtInstrumentNumberOfUnsecuredNotesEntered	7	note
CY2016Q1	mbrx	Debt Instrument Unsecured Notes Number Of Third Party Investors DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors	3	investor
CY2016Q2	mbrx	Decrease In Convertible Notes Payable Current DecreaseInConvertibleNotesPayableCurrent	180000	USD
CY2017Q3	mbrx	Estimated Forfeiture Rate Percentage EstimatedForfeitureRatePercentage	0
CY2016Q3	mbrx	Gain From Settlement Liability GainFromSettlementLiability	0	USD
	mbrx	Gain From Settlement Liability GainFromSettlementLiability	0	USD
CY2017Q3	mbrx	Gain From Settlement Liability GainFromSettlementLiability	0	USD
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21136059	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	mbrx	Gain From Settlement Liability GainFromSettlementLiability	149000	USD
CY2016Q3	mbrx	Gain Loss From Expiration Of Warrants GainLossFromExpirationOfWarrants	0	USD
	mbrx	Gain Loss From Expiration Of Warrants GainLossFromExpirationOfWarrants	0	USD
CY2017Q3	mbrx	Gain Loss From Expiration Of Warrants GainLossFromExpirationOfWarrants	0	USD
	mbrx	Gain Loss From Expiration Of Warrants GainLossFromExpirationOfWarrants	1238000	USD
	dei	Entity Registrant Name EntityRegistrantName	Moleculin Biotech, Inc.
	dei	Trading Symbol TradingSymbol	MBRX
CY2016Q2	mbrx	Licensing Agreement Term LicensingAgreementTerm	P3Y
	mbrx	Numberof Drug Candidates NumberofDrugCandidates	4	candidate
	mbrx	Proceedsfrom Issuanceof Common Stock Netof Issuance Costs ProceedsfromIssuanceofCommonStockNetofIssuanceCosts	9167000	USD
	mbrx	Adjustmentsto Additional Paidin Capital Saleof Common Stockin Atm Offering Issuance Costs AdjustmentstoAdditionalPaidinCapitalSaleofCommonStockinATMOfferingIssuanceCosts	47000	USD
	mbrx	Adjustmentsto Additional Paidin Capital Stock Warrants Exercised During Period Issuance Costs AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts	80000	USD
	mbrx	Proceedsfrom Issuanceof Common Stock Netof Issuance Costs ProceedsfromIssuanceofCommonStockNetofIssuanceCosts	4867000	USD
CY2017Q3	mbrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	1.66
CY2016Q2	mbrx	Shares Authorized SharesAuthorized	80000000	shares
CY2017Q1	mbrx	Stock Issued During Period Shares For Cash Initial Public Offering Net Of Stock Issuance Costs StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts	3710000	shares
	mbrx	Stock Issued During Period Value For Cash Initial Public Offering Net Of Stock Issuance Costs StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts	317000	USD
	mbrx	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	8756000	USD
	mbrx	Stock Issued During Period Valuefor Cash Atm Netof Stock Issuance Costs StockIssuedDuringPeriodValueforCashATMNetofStockIssuanceCosts	360000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1069000	USD
CY2017Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1089000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	19623000	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	29925000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	487000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	550000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	200000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	500000	USD
CY2016Q4	us-gaap	Assets Assets	16393000	USD
CY2017Q3	us-gaap	Assets Assets	20633000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	5222000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	9463000	USD
CY2016Q2	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	750000.00	USD
CY2016Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	1000000.0	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6184000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5007000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8736000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6156000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3729000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12164852	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20822214	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12164852	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20822214	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	12000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	21000	USD
CY2016Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	276000	USD
CY2017Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2017Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	100000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	342000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	302000	USD
CY2016Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	1166503	shares
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	2920738	shares
CY2017Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	804098	shares
	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	88000	USD
	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	62000	USD
CY2016Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	88000	USD
CY2017Q3	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	150000	USD
CY2016Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2000	USD
CY2017Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13000	USD
CY2016Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0	USD
CY2017Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	743000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y4M1D
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1600000	USD
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1060000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3300000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1240000	USD
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	470000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2753000	USD
CY2016	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P0Y
CY2016	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0
CY2016	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-1432000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2503000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12000	USD
CY2016Q2	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-20000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2596000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-30000	USD
CY2016	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	20000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4934000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	924000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1848000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1338000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2987000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-147000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	285000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	245000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	518000	USD
CY2016Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	11148000	USD
CY2017Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	11148000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	10000	USD
	us-gaap	Interest Expense InterestExpense	37000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	1000	USD
	us-gaap	Interest Expense InterestExpense	2000	USD
	us-gaap	Interest Paid InterestPaid	48000	USD
	us-gaap	Interest Paid InterestPaid	2000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	1433000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	1982000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16393000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20633000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1345000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1832000	USD
CY2017Q3	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	743000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8862000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8675000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-110000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-2866000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6620000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	1422000	USD
	us-gaap	Operating Expenses OperatingExpenses	2466000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	2404000	USD
	us-gaap	Operating Expenses OperatingExpenses	5260000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1422000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2466000	USD
CY2016Q3	us-gaap	Other Income OtherIncome	0	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2404000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5260000	USD
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	215000	USD
	us-gaap	Other Income OtherIncome	0	USD
CY2017Q3	us-gaap	Other Income OtherIncome	9000	USD
	us-gaap	Other Income OtherIncome	8000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	9000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	100000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	727000	USD
CY2017Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1240000	USD
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	400000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	165000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	800000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3808000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	470000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	497000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	616000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1061000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2260000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4675000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11300000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11295000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	209000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	487000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	85000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.79
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	117300	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	160000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.52
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	275500	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	144900	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	510000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	670000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.28
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.78
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.14
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y1M24D
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.40
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.12
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M14D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M6D
CY2017Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.35
	us-gaap	Stock Issued1 StockIssued1	9774000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	302000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	89000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	14960000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	18651000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11579239	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9066804	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20534720	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17683441	shares
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reclassifications –</font><font style="font-family:inherit;font-size:10pt;"> A reclassification was made to the </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> financial statements to conform to the </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> presentation. Such reclassification did not affect net loss as previously reported. Historically, accrued interest associated with “convertible notes payable” was included in the line item “accounts payable and accrued expense”.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates in Financial Statement Presentation -</font><font style="font-family:inherit;font-size:10pt;"> The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001659617-17-000005-index-headers.html	Edgar Link	pending
0001659617-17-000005-index.html	Edgar Link	pending
0001659617-17-000005.txt	Edgar Link	pending
0001659617-17-000005-xbrl.zip	Edgar Link	pending
a2017q310q.htm	Edgar Link	pending
a2017q3ex311.htm	Edgar Link	pending
a2017q3ex312.htm	Edgar Link	pending
a2017q3ex321.htm	Edgar Link	pending
a2017q3ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mbrx-20170930.xml	Edgar Link	completed
mbrx-20170930.xsd	Edgar Link	pending
mbrx-20170930_cal.xml	Edgar Link	unprocessable
mbrx-20170930_def.xml	Edgar Link	unprocessable
mbrx-20170930_lab.xml	Edgar Link	unprocessable
mbrx-20170930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v471975_img01.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MBRX
Moleculin Biotech, Inc. Stock $mbrx

2017 Q4 Form 10-Q Financial Statement

#000165961717000005 Filed on November 13, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBRX Moleculin Biotech, Inc. Stock $mbrx

2017 Q4 Form 10-Q Financial Statement

#000165961717000005 Filed on November 13, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBRX
Moleculin Biotech, Inc. Stock $mbrx